Thyroid cancer, recent advances in diagnosis and therapy
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Over the past several decades, the approach to the diagnosis and management of patients with follicular cell‐derived thyroid cancer has evolved based on improved classification of patients better matching clinical outcomes, as well as advances in imaging, laboratory, molecular technologies and knowledge. While thyroid surgery, radioactive iodine therapy and TSH suppression remain the mainstays of treatment, this expansion of knowledge has enabled de‐escalation of therapy for individuals diagnosed with low‐risk well‐differentiated thyroid cancer; better definition of treatment choices for patients with more aggressive disease; and improved ability to optimize treatments for patients with persistent and/or progressive disease. Most recently, the advancement of knowledge regarding the molecular aspects of thyroid cancer has improved thyroid cancer diagnosis and has enabled individualized therapeutic options for selected patients with the most aggressive forms of the disease. Guidelines from multiple societies across the world reflect these changes, which focus on taking a more individualized approach to clinical management. In this review, we discuss the current more personalized approach to patients with follicular cell‐derived thyroid cancer and point toward areas of future research still needed in the field.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Haugen, B. R., Alexander, E. K., Bible, K. C., Doherty, G. M., Mandel, S. J., Nikiforov, Y. E., Pacini, F., Randolph, G. W., Sawka, A. M., Schlumberger, M., et al. (2016) · Thyroid® · doi:10.1089/thy.2015.0020 · Cited by 16,535
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
Drilon, A., Laetsch, T. W., Kummar, S., DuBois, S. G., Lassen, U. N., Demetri, G. D., Nathenson, M., Doebele, R. C., Farago, A. F., Pappo, A. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714448 · Cited by 2,824
Trends in Thyroid Cancer Incidence and Mortality in the United States, 1974-2013
Lim, H., Devesa, S. S., Sosa, J. A., Check, D., & Kitahara, C. M. (2017) · JAMA · doi:10.1001/jama.2017.2719 · Cited by 2,159
Doebele, R. C., Drilon, A., Paz-Ares, L., Siena, S., Shaw, A. T., Farago, A. F., Blakely, C. M., Seto, T., Cho, B. C., Tosi, D., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30691-6 · Cited by 1,790
Worldwide Thyroid-Cancer Epidemic? The Increasing Impact of Overdiagnosis
Vaccarella, S., Franceschi, S., Bray, F., Wild, C. P., Plummer, M., & Dal Maso, L. (2016) · New England Journal of Medicine · doi:10.1056/nejmp1604412 · Cited by 1,145
Verloop, H., Louwerens, M., Schoones, J. W., Kievit, J., Smit, J. W. A., & Dekkers, O. M. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1063 · Cited by 220
Wang, L. Y., Smith, A. W., Palmer, F. L., Tuttle, R. M., Mahrous, A., Nixon, I. J., Patel, S. G., Ganly, I., Fagin, J. A., & Boucai, L. (2015) · Thyroid · doi:10.1089/thy.2014.0287 · Cited by 161
Biondi, B., & Cooper, D. S. (2018) · New England Journal of Medicine · doi:10.1056/nejmcp1709318 · Cited by 135
Metadata
- Authors
- Nabhan, F., Dedhia, P. H., & Ringel, M. D.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2021-05-29
- Volume
- 149
- Issue
- 5
- Pages
- 984-992
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W3161656085
- Cited by
- 214
- References
- 9
- FWCI
- 17.60
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Thyroid cancer, recent advances in diagnosis and therapy. https://app.cochat.ai/papers/10.1002/ijc.33690
- The paper
- Nabhan, F., Dedhia, P. H., & Ringel, M. D. (2021). Thyroid cancer, recent advances in diagnosis and therapy. International Journal of Cancer. https://doi.org/10.1002/ijc.33690
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.